- ProBioGen will provide high-performance cell line development for a biosimilar candidate from Polpharma Biologics.
- The agreement includes use of ProBioGen’s CHO.RiGHT platform with proprietary DirectedLuck technology.
ProBioGen has entered into an agreement with Polpharma Biologics to deliver high-performance cell line development services for an unnamed biosimilar candidate. The collaboration aims to support Polpharma’s growing biosimilar pipeline.
The work will be carried out using ProBioGen’s CHO.RiGHT platform, which includes the proprietary DirectedLuck transposase technology. This approach is designed to ensure a high-yielding, stable cell line that aligns with the biosimilar’s critical quality attributes.
The services will be provided by ProBioGen, a contract manufacturing organisation (CDMO) with a track record in biologics and biosimilar development. Cell line development is considered a critical early step in the production of biological therapies, as highlighted by the industry’s guiding principle: “the process defines the product.”
Dr. Volker Sandig, Chief Scientific Officer at ProBioGen, said: “We are excited to support Polpharma Biologics in bringing their product to the clinic… [with] best-in-class expression platform that ensures efficiency, expression stability and superior quality.”
Dr. Konstantin Matentzoglu, Supervisory Board Member from Polpharma Biologics, noted that ProBioGen’s capabilities as a reliable CDMO were a key factor in forming the partnership. The collaboration reflects both companies’ commitment to advancing access to affordable biologics.
